Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12039753 | 0.93 | PIK3CD (0.56) | PIK3CDCYP1A2MAPK1MEN1KMT2A | |
| SCHEMBL13181450 | 0.91 | PIK3CD (0.54) | PIK3CDCYP1A2MAPK1MEN1KMT2A | |
| SCHEMBL21148619 | 0.88 | PIK3CD (0.56) | PIK3CDCYP1A2MAPK1MEN1KMT2A | |
| SCHEMBL16850424 | 0.88 | PIK3CD (0.56) | PIK3CDCYP1A2MAPK1MEN1KMT2A | |
| SCHEMBL23374624 | 0.86 | PIK3CD (0.54) | PIK3CDCYP1A2MAPK1MEN1KMT2A | |
| SCHEMBL13519632 | 0.82 | PIK3CD (0.54) | PIK3CDMEN1KMT2A | |
| SCHEMBL12039809 | 0.82 | PIK3CD (0.54) | PIK3CDMEN1KMT2A | |
| SCHEMBL15332378 | 0.81 | PIK3CD (0.48) | PIK3CDMEN1KMT2A | |
| SCHEMBL20034180 | 0.80 | PIK3CD (0.46) | PIK3CDMEN1KMT2A | |
| SCHEMBL12971735 | 0.80 | PIK3CD (0.46) | PIK3CDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938245-B2 | Carbonyl erastin analogs and their use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-04-10 | — | — | US | disclosed |
| US-9695133-B2 | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160332974-A1 | CARBONYL ERASTIN ANALOGS AND THEIR USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332974-A1 | CARBONYL ERASTIN ANALOGS AND THEIR USE | KEAP1, GPX1, GPX4 | PIK3CD 2693/4885CYP1A2 2039/4885MAPK1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.